Joel David Mayersohn - Jul 28, 2025 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Role
Director
Signature
/s/ Alexander M. Donaldson, by Power of Attorney
Stock symbol
CTOR
Transactions as of
Jul 28, 2025
Transactions value $
$0
Form type
4
Date filed
8/7/2025, 05:02 PM
Previous filing
Dec 16, 2024
Next filing
Sep 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mayersohn Joel David Director C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD /s/ Alexander M. Donaldson, by Power of Attorney 2025-08-07 0001588395

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTOR Common Stock Other $0 +21.2K $0.00 21.2K Jul 28, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTOR Stock Option (Right to Buy) 250K Jul 28, 2025 Common Stock 250K $1.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc.
F2 The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.